Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.36 |
| ▸ | AURKA | O14965 | 6/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527508 | 0.91 | HPGD (0.45) | FFAR1AURKARPS6KB1HPGDXBP1 | |
| SCHEMBL2526628 | 0.89 | AURKA (0.39) | FFAR1AURKARPS6KB1GPR88MAPT | |
| SCHEMBL2531263 | 0.89 | FFAR1 (0.35) | FFAR1AURKARPS6KB1GPR88MAPT | |
| SCHEMBL2528486 | 0.88 | ESR1 (0.39) | FFAR1AURKARPS6KB1NPSR1MEN1 | |
| SCHEMBL2529616 | 0.87 | GPR88 (0.33) | AURKARPS6KB1GPR88 | |
| SCHEMBL2526970 | 0.87 | CYP1A2 (0.38) | FFAR1AURKARPS6KB1CYP1A2CYP2D6 | |
| SCHEMBL2527399 | 0.87 | SLC6A2 (0.41) | AURKARPS6KB1GPR88MAPTKMT2A | |
| SCHEMBL2529745 | 0.87 | KMT2A (0.40) | FFAR1AURKARPS6KB1HPGDXBP1 | |
| SCHEMBL2526878 | 0.86 | FFAR1 (0.34) | FFAR1AURKARPS6KB1CYP1A2CYP2D6 | |
| SCHEMBL2525580 | 0.86 | CYP26A1 (0.32) | FFAR1AURKARPS6KB1GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039501-B2 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2011-10-18 | — | — | US | disclosed |
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | HRH1, HRH3, HRH2 | FFAR1 60/4885AURKA 2197/4885RPS6KB1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.